Buy on positive interim data — 29% ORR in heavily pretreated PROC is a clinically meaningful signal for a CLDN6 x CD3 TCE, especially with manageable CRS profile that supports outpatient dosing. Expect significant upward revaluation at open. Key catalysts ahead: Q3W PK/PD data in H2 2026, then Phase 1b expansion in 2027. Fast Track designation may accelerate regulatory pathway.
Price Chart
Executive Summary
Context Therapeutics reported positive interim Phase 1 data for its CLDN6 x CD3 TCE bispecific antibody, CTIM-76, showing a 29% confirmed overall response rate (RECIST v1.1) in heavily pretreated platinum-resistant ovarian cancer (PROC) patients, with manageable safety (Grade 1 CRS in 11% of patients at active doses). The FDA has granted Fast Track Designation, and the company expects to explore Q3W dosing in H2 2026, with Phase 1b dose expansion planned for 2027. For a $128M market cap clinical-stage biotech, this represents a meaningful catalyst de-risking the CTIM-76 program and supporting the company's broader TCE platform.
Key Facts
- 29% confirmed ORR (2/7) per RECIST v1.1 in platinum-resistant ovarian cancer patients at active doses 140µg-280µg QW
- 57% disease control rate (4/7) in PROC efficacy-evaluable patients at active doses
- Patients had median 7 prior lines of therapy (range 5-16), 89% prior ADC exposure, 55% prior checkpoint inhibitors
- CRS limited to Grade 1 in 11% (1/9) of PROC patients at active doses — supports outpatient dosing
- FDA granted Fast Track Designation for CTIM-76 in PROC
- PK profile supports exploration of every-3-week (Q3W) dosing starting H2 2026
- Phase 1b dose expansion expected in 2027
- CTIM-76 targets CLDN6, enriched in ovarian, endometrial, lung, gastric, and testicular cancers
Financial Impact
For a $128M market cap, positive Phase 1 data with 29% ORR in late-line PROC (typically resistant settings) is transformative — could add 50-100%+ upside if results replicate in expansion. No financial terms or deal value disclosed.
Risk Factors
- Phase 1a data based on only 7 evaluable PROC patients — small sample, ORR could decline in larger cohorts
- Competing CLDN6-targeted therapies in development (e.g., by BioNTech, other biotechs) could limit commercial differentiation
- Q3W dosing exploration is preliminary — PK/PD data required to confirm feasibility and maintain efficacy
- Early-stage biotech with no approved products — financing risk ahead of Phase 1b/2 milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 15, 2026 19w ago | 8-K | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2400 (−64.66%) |
Jun 15, 2026 19w ago | Press Release | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2400 (−64.66%) |
May 18, 2026 23w ago | PRESS-RELEASE / 8-K | $2.15 $2.63 | ▲ +22.33% | ▲ +20.71% | $0.2400 (−88.84%) |
May 6, 2026 24w ago | Press Release | $2.33 $2.36 | ▲ +1.29% | ▼ −0.22% | $0.2400 (−89.70%) |
May 1, 2026 25w ago | 8-K | $2.30 $2.39 | ▲ +3.91% | ▲ +0.98% | $0.2400 (−89.57%) |
Apr 2, 2026 29w ago | 8-K | $2.72 $2.49 | ▼ −8.46% | ▼ −12.07% | $0.2400 (−91.18%) |
Mar 23, 2026 31w ago | Press Release | $3.18 $2.62 | ▼ −17.61% | ▼ −17.19% | $0.2400 (−92.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers